(51) International Patent Classification 5:
A61M 31/00

(11) International Publication Number:
WO 94/02199

(21) International Application Number:
PCT/US93/06596

(22) International Filing Date:
14 July 1993 (14.07.93)

(30) Priority data:
916,332

16 July 1992 (16.07.92)

US

(71) Applicant:
TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION [US/US]; Broad Street And Montgomery Avenue, Philadelphia, PA 19121 (US).

(72) Inventors:

(74) Agent:

(81) Designated States:

Published
With international search report.

(54) Title:
TREATMENT OF PHYSIOLOGICAL CONDITIONS WITH DEGASSED PERFLUOROCARBON LIQUID

---

This invention pertains to the use of a degassed perfluorocarbon ("PFC") liquid as a method of removing gas emboli from parts of a patient's body cavity. Moreover, the invention can be used as a method of imaging parts of a patient's body cavity. Furthermore, the invention can also be used as a way of delivering biological agents to parts of a patient's body cavity which contain or are surrounded by gas emboli and/or which are to be imaged. In this invention, a degassed PFC liquid is delivered to a region within the patient's body cavity which contains gas emboli and/or which is to be imaged. If gas emboli are present, the degassed liquid is permitted to absorb at least a portion of the emboli. Thereafter, the emboli-containing liquid is removed from the patient or is used as an imaging agent. If gas emboli are not present, the site is imaged before the degassed liquid reaches atmospheric equilibrium. Thereafter, the liquid is removed from the patient. Moreover, by mixing a biological agent with the degassed PFC liquid, the mixture can be used as a way of topically treating parts within a patient's body cavity. Furthermore, by regulating the temperature of the degassed liquid, it can also be used as a way of hypo- or hyperthermically treating the patient.
**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AT</td>
<td>Austria</td>
<td>FR</td>
<td>France</td>
<td>MR</td>
<td>Mauritania</td>
</tr>
<tr>
<td>AU</td>
<td>Australia</td>
<td>GA</td>
<td>Gabon</td>
<td>MW</td>
<td>Malawi</td>
</tr>
<tr>
<td>BB</td>
<td>Barbados</td>
<td>GB</td>
<td>United Kingdom</td>
<td>NE</td>
<td>Niger</td>
</tr>
<tr>
<td>BE</td>
<td>Belgium</td>
<td>GN</td>
<td>Guinea</td>
<td>NL</td>
<td>Netherlands</td>
</tr>
<tr>
<td>BF</td>
<td>Burkina Faso</td>
<td>GR</td>
<td>Greece</td>
<td>NO</td>
<td>Norway</td>
</tr>
<tr>
<td>BG</td>
<td>Bulgaria</td>
<td>HU</td>
<td>Hungary</td>
<td>NZ</td>
<td>New Zealand</td>
</tr>
<tr>
<td>BJ</td>
<td>Benin</td>
<td>IE</td>
<td>Ireland</td>
<td>PL</td>
<td>Poland</td>
</tr>
<tr>
<td>BR</td>
<td>Brazil</td>
<td>IT</td>
<td>Italy</td>
<td>PT</td>
<td>Portugal</td>
</tr>
<tr>
<td>BY</td>
<td>Belarus</td>
<td>JP</td>
<td>Japan</td>
<td>RO</td>
<td>Romania</td>
</tr>
<tr>
<td>CA</td>
<td>Canada</td>
<td>KP</td>
<td>Democratic People’s Republic of Korea</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CG</td>
<td>Central African Republic of Congo</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CH</td>
<td>Switzerland</td>
<td>KR</td>
<td>Republic of Korea</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CI</td>
<td>Côte d’Ivoire</td>
<td>KZ</td>
<td>Kazakhstan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CM</td>
<td>Cameroon</td>
<td>LIE</td>
<td>Liechtenstein</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CN</td>
<td>China</td>
<td>LI</td>
<td>Sri Lanka</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CS</td>
<td>Czechoslovakia</td>
<td>LU</td>
<td>Luxembourg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CZ</td>
<td>Czech Republic</td>
<td>LV</td>
<td>Latvia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DE</td>
<td>Germany</td>
<td>MC</td>
<td>Monaco</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DK</td>
<td>Denmark</td>
<td>MG</td>
<td>Madagascar</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ES</td>
<td>Spain</td>
<td>ML</td>
<td>Mali</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FI</td>
<td>Finland</td>
<td>MN</td>
<td>Mongolia</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>RU</td>
<td>Russian Federation</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SD</td>
<td>Sudan</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SE</td>
<td>Sweden</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SI</td>
<td>Slovenia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SK</td>
<td>Slovak Republic</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SN</td>
<td>Senegal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TO</td>
<td>Chad</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TG</td>
<td>Togo</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>UA</td>
<td>Ukraine</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>US</td>
<td>United States of America</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>UZ</td>
<td>Uzbekistan</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>VN</td>
<td>Viet Nam</td>
</tr>
</tbody>
</table>
TREATMENT OF PHYSIOLOGICAL CONDITIONS WITH DEGASSED PERFLUOROCARBON LIQUID

Field Of The Invention

The invention relates to the use of degassed perfluorocarbon liquid ingestion and/or infusion as a means for controlling, treating and/or diagnosing physiological conditions within a patient. In particular, degassed perfluorocarbon liquid can be used as a means for imaging parts of a patient's body cava, as a means for delivering biological agents to parts of a patient's body cava, and/or as a means for absorbing gas(es) from parts of a patient's body cava.

Background Of The Invention

It is known to use "gassed" (e.g., oxygenated) perfluorocarbon liquids as a means for delivering gases (e.g., oxygen) to certain parts of a patient's pulmonary and/or vascular systems. Moreover, it is also known to use atmospheric-equilibrated perfluorocarbon liquids as a contrast mediums for imaging purposes.

This invention pertains to novel applications of "degassed" perfluorocarbon liquids. Specifically, the present invention pertains to using degassed perfluorocarbon liquids as a means for controlling, treating and/or diagnosing certain physiological conditions, diseases and/or abnormalities of a patient which were, heretofore, difficult or impossible to control, treat and/or diagnose.
Definitions

As used herein, the term "gassed perfluorocarbon liquid" refers to a perfluorocarbon liquid which has been forced to absorb gas(es) such that the total concentration of gas contained therein is greater than that present in the same liquid at atmospheric equilibrium conditions.

As used herein, the term "oxygenated perfluorocarbon liquid" refers to a specific type of gassed perfluorocarbon liquid which has been forced to absorb oxygen such that the total concentration of oxygen contained therein is greater than that present in the same liquid at atmospheric equilibrium conditions.

As used herein, the term "degassed perfluorocarbon liquid" refers to a perfluorocarbon liquid which has been forced to release gas(es) such that the total concentration of gas contained therein is less than that present in the same liquid at atmospheric equilibrium conditions.

As used herein, the term "atmospheric-equilibrated perfluorocarbon liquid" refers to a perfluorocarbon liquid having a concentration of gas contained therein which is substantially the same as that present in the same liquid prior to being gassed or degassed.

As used herein, the term "body cava" refers to cavities, spaces, voids and/or gaps present in and/or around regions, parts, and/or organs within a patient's body cava. Various locations within a patient's body cava encompassed by the term "body cava", include, without limitation, cavities, spaces, voids and/or gaps present in and/or around the patient's gastrointestinal track, uterus, bladder, nasal cavity, sinus cavity and acoustic canal. However, the term "body cava" is not intended to include cavities, spaces voids and/or gaps in the patient's pulmonary track.
Summary of the Invention

One object of this invention is to provide a novel means for removing gas emboli from a patient's body cava.

Another object of this invention is to provide a novel means for imaging portions of a patient's body cava.

Yet another object of this invention is to provide a novel means for imaging portions of a patient's body cava which contain and/or are at least partially surrounded by gas emboli.

Even another object of this invention is to provide a novel means for delivering biological agents to locations within a patient's body cava which are to be imaged.

A further object of this invention is to provide a novel means for delivering biological agents to locations within a patient's body cava which contain and/or are at least partially surrounded by gas emboli.

Even a further object of the present invention is to provide a novel means for delivering biological agents to locations within a patient's body cava which contain and/or are at least partially surrounded by gas emboli and which are to be imaged.

Still another object of this invention is to provide a novel means for using a perfluorocarbon liquid for the manufacture of a material for use in a process for removing gas emboli from a patient's body cava.

One embodiment of this invention pertains to the use of a degassed perfluorocarbon ("PFC") liquid as a novel means for removing gas emboli from a patient's body cava. In this embodiment, gas emboli within a patient's body cava are removed by a process which comprises the following steps: (a) degassing a PFC liquid, (b) delivering the degassed PFC liquid to a region within the patient's body cava containing a gas emboli, (c) permitting the degassed PFC liquid to absorb at least a portion of the gas emboli, and (d) removing from the patient's body cava the emboli-containing PFC liquid.
Another embodiment of this invention pertains to the use of a degassed PFC liquid as a novel means for imaging parts of a patient's body cava. In this embodiment, parts of a patient's body cava can be imaged by a process which comprises the following steps: (a) degassing a PFC liquid, (b) delivering the degassed PFC liquid to a region within the patient's body cava which is to be imaged, (c) imaging the region within the patient's body cava to which the degassed PFC liquid was delivered, and (d) removing from the patient's body cava the PFC liquid.

Yet another embodiment of this invention pertains to the use of a degassed PFC liquid as a novel means for imaging parts of a patient's body cava which contain and/or are at least partially surrounded by gas emboli. In this embodiment, such parts of a patient's body cava can be imaged by a process which comprises the following steps: (a) degassing a PFC liquid, (b) delivering the degassed PFC liquid to a region within the patient's body cava which is to be imaged and which contains and/or is at least partially surrounded by a gas emboli, (c) permitting the degassed PFC liquid to absorb at least a portion of the gas emboli, (d) imaging the region within the patient's body cava which contained or was surrounded by the gas emboli, and (e) removing from the patient's body cava the emboli-containing PFC liquid.

Even another embodiment of this invention pertains to the use of a degassed PFC liquid as a novel means for delivering biological agents to parts of a patient's body cava which are to be imaged. In this embodiment, biological agents can be provided to such parts of a patient's body cava by a process which comprises the following steps: (a) degassing a PFC liquid, (b) mixing a biological agent with the degassed PFC liquid to form an agent-containing PFC liquid, (c) delivering the agent-containing PFC liquid to a region within the patient's body cava which is to be imaged, (d) permitting at least some of the biological agent to be released from the agent-containing PFC liquid, (e) imaging the region within the patient's body cava to which the agent-containing PFC liquid was delivered, and (f) removing from the patient's body cava the PFC liquid.
A further embodiment of this invention pertains to the use of a degassed PFC liquid as a novel means for delivering biological agents to parts of a patient's body cava which contain and/or are at least partially surrounded by gas emboli. In this embodiment, biological agents can be provided to such parts of a patient's body cava by a process which comprises the following steps: (a) degassing a PFC liquid, (b) mixing a biological agent with the degassed PFC liquid to form an agent-containing PFC liquid, (c) delivering the agent-containing PFC liquid to a region within the patient's body cava which contains and/or is at least partially surrounded by a gas emboli, (d) permitting the agent-containing PFC liquid to absorb at least a portion of the gas emboli, (e) permitting at least some of the biological agent to be released from the agent-containing PFC liquid, and (f) removing from the patient's body cava the emboli-containing PFC liquid.

Even a further embodiment of this invention pertains to the use of a degassed PFC liquid as a novel means for delivering biological agents to parts of a patient's body cava which are to be imaged and which contain and/or are at least partially surrounded by gas emboli. In this embodiment, biological agents can be provided to such parts of a patient's body cava by a process which comprises the following steps: (a) degassing a PFC liquid, (b) mixing a biological agent with the degassed PFC liquid to form an agent-containing PFC liquid, (c) delivering the agent-containing PFC liquid to a region within the patient's body cava which is to be imaged and which contains and/or is at least partially surrounded by a gas emboli, (d) permitting the agent-containing PFC liquid to absorb at least a portion of the gas emboli, (e) permitting at least some of the biological agent to be released from the agent-containing PFC liquid, (f) imaging the region within the patient's body cava to which the PFC liquid was delivered, and (g) removing from the patient's body cava the emboli-containing PFC liquid.

These and other objects, embodiments and aspects of the present invention will become apparent to those skilled in the art upon reading the following detailed description.
Brief Description Of The Drawings

A more complete appreciation of the invention will be readily obtained as the same becomes better understood by reference to the following detailed description and the accompanying figures briefly described below.

FIGURE 1 is a print-out from a pressure transducer showing the changes in bowel motility resulting from infusing a neat, degassed PFC liquid into the bowel of a neonatal lamb.

FIGURE 2 is a print-out from a pressure transducer showing the changes in bowel motility resulting from infusing a mixture of a degassed PFC liquid and epinephrine into the bowel of a neonatal lamb.

FIGURE 3 is a print-out from a pressure transducer showing the changes in bowel motility resulting from infusing a mixture of a PFC liquid and acetylcholine into the bowel of a neonatal lamb.

FIGURE 4 is a graph plotting the attenuating effects of gas saturation on a PFC liquid.

FIGURE 5 is a graph plotting the cavitation threshold of a PFC liquid based upon the liquid's temperature and gas saturation level.

Detailed Description Of The Invention

The presence of gas emboli which are in and/or around certain parts of a patient's body cava have been the source of many different types of problems to the patient and the medical practitioner. For example, their presence can subject a patient to severe health hazards. Specifically, their presence may have adverse effects on the internal body parts which they are in and/or around. Moreover, their presence may hinder the imaging of certain internal body parts; thus, rendering this highly useful diagnostic tool ineffective. Furthermore, their presence may also hinder the treatment of certain internal body parts with the appropriate biological agents. This invention provides a novel process which resolves each of the above problems.
In addition to the above, this invention also provides a novel process for performing the following procedures: imaging regions within a patient's body cava; and, delivering biological agents to parts of a patient's body cava which are to be imaged.

The present invention provides novel uses for degassed PFC liquids. Any suitable PFC liquid can be used when practicing this invention. Suitable PFC liquids include those liquids characterized by an average molecular weight, of the PFC constituent(s), in the range from about 350 to about 560. Such PFC liquids are alternatively characterized by having a viscosity less than about 5 CP at 25°C, a density less than about 2.0 g/cm³ at 25°C, a boiling point greater than about 55°C, a vapor pressure greater than about 20 Torr but less than about 200 Torr at 25°C, a surface tension less than about 17 dyne/cm at 25°C, and a Prandt number less than about 10 at 25°C. For use in the present invention, the PFC liquid should also preferably have an oxygen solubility greater than about 40 ml/100 ml. Representative PFC liquids that meet the aforementioned criteria include, without limitation, FC-84, FC-72, RM-82, FC-75 (3M Company, Minneapolis, Minnesota), RM-101 (MDI Corporation, Bridgeport, Connecticut), dimethyladamantane (Sun Tech., Inc.), trimethylbicyclononane (Sun Tech., Inc.), and perfluorodecalin (Green Cross Corp., Japan).

The most preferred PFC liquid depends upon the specific body cava of the patient within which it will be introduced.

For those instances in the practice of the present invention where the presence of gas emboli has an adverse effect on a patient's physiological condition, one embodiment of this invention provides a novel means for their removal through the use of a degassed PFC liquid. Here, a suitable PFC liquid is at least partially degassed. The level to which the PFC liquid is degassed depends, in part, upon the size and location of the gas emboli.

When practicing any embodiment of the present invention, the PFC liquids can be degassed by any means known to those skilled in the art.

In one of the more preferred degassing methods, a vacuum source is attached
to a sealed reservoir containing an atmospheric-equilibrated PFC liquid. Generally, this vacuum source is at least about -30 mm Hg.

The driving force created by the vacuum vaporizes the PFC liquid. The vaporized PFC liquid is condensed by being drawn through a cold condenser unit. The condensed PFC vapor has a gas concentration less than that within the atmospheric-equilibrated PFC liquid. In order to prevent reabsorption, gases which were evacuated during the condensation process are appropriately vented.

After the PFC liquid has been degassed to the desired level, it is delivered to that region within the patient's body cava which contains the gas emboli to be removed. Any suitable means can be used to deliver the degassed PFC liquid to the appropriate region. Examples of suitable delivery techniques include, without limitation, ingestion, injection, inhalation and infusion. The preferred delivery technique depends, in part, upon the location of the emboli.

When the degassed PFC liquid comes into contact with the gas emboli, the liquid will begin to absorb the gas. Generally, the PFC liquid is permitted to remain at that location until the emboli is completely absorbed by the PFC liquid or until the degassed PFC liquid has reached equilibrium. However, it is within the scope of this invention to terminate the absorption process before the emboli is completely absorbed and before the degassed PFC liquid has reached equilibrium, if so desired.

After the PFC liquid has absorbed the desired amount of the gas emboli, the now emboli-containing PFC liquid is removed from the patient's body cava. This PFC liquid can be removed by any suitable means. For example, the emboli-containing PFC liquid can be physically withdrawn and/or drained via appropriate medical devices (e.g., a syringe, a catheter, etc.), or withdrawn via natural means (e.g., through normal body excretions). If the gas emboli was not completely removed, the aforementioned process can be repeated, if so desired.
Heretofore, the medical profession was not aware of such a process for the removal of gas emboli from a patient's body cava. Accordingly, this embodiment of the invention, opens many new avenues for treating patients which have been plagued by the presence of gas emboli in these regions.

Another problem resolved by this invention pertains to those instances where the presence of gas emboli hinders the clear imaging of certain regions of a patient's body cava. Specifically, a highly useful diagnostic tool in the medical profession is the imaging of such regions by non-invasive procedures such as ultrasonic imaging and MRI imaging. If gas emboli are present in and/or around the particular region being imaged, their presence can decrease the clarity of the image. Depending upon the amount of gas emboli present and the imaging technique being employed, their presence can render the resulting image completely unusable. In this embodiment, a degassed PFC liquid is delivered to the region within the patient's body cava which is to be imaged and which contains and/or is at least partially surrounded by gas emboli.

As stated above, any suitable means can be used for degassing the PFC liquid. However, in order to serve as a suitable imaging medium, the PFC liquid should preferably have the following physical properties: viscosity less than about 5 CP at 25°C, density less than about 2.0 g/cm³ at 25°C, boiling point greater than about 75°C, vapor pressure greater than about 25 Torr and less than about 100 Torr, acoustical impedance between about 0.8 to about 1.6 Mega Rayls at 37°C, and acoustical attenuation less than about 1.1 dB/cm (±20%) at 1.0 MHz and at 45°C, and acoustical intensity of about 3 W/cm².

It is also preferred that, when practicing this embodiment of the invention, the PFC liquid is characterized by an oxygen solubility greater than about 40 ml/100 ml. PFC liquids having an average molecular weight in the range of from about 400 to about 500 generally satisfy the above criteria, with the preferred group in terms of optimizing the imaging properties having an average molecular weight in the range of from about 400 to about 460, and most preferably in the range of from about 420 to about 460. Representative of this most preferred
group of PFC liquids include, without limitation, FC-75, RM-101 and perfluorodecalin.

When practicing this embodiment of the present invention, the degassed PFC liquid is permitted to stay in contact with the emboli until at least a portion of the emboli is absorbed thereby. Preferably, the PFC liquid is permitted to stay in contact with the emboli until the gas is completely absorbed thereby or until equilibrium conditions are reached. If equilibrium is reached before the gas emboli is completely removed from the imaging site, it is presently preferred to repeat this process since the presence of gas emboli often decreases the clarity of most images.

After a sufficient amount of the gas emboli has been removed from or around the site which is to be imaged, the imaging process is commenced. Due to the excellent imaging properties of PFC liquids, it is presently preferred to keep the liquid at the imaging site during the imaging process.

When the PFC liquid absorbs the gas emboli, the resultant composition is not a two phase mixture. Rather, the emboli is dissolved into the PFC liquid to form a homogenous solution. Although it has been discovered that the imaging properties of a degassed PFC liquid are better than those of a similar atmosphere-equilibrated PFC liquid (the specifics of this discovery will be discussed later), in many instances, the imaging properties of an atmosphere-equilibrated PFC liquid are satisfactory. Therefore, unless exceptional clarity is desired, the emboli-containing PFC liquid can be retained at the imaging site throughout the imaging process.

Notwithstanding the above, it is also within the purview of this invention to replace the emboli-containing PFC liquid with a degassed liquid prior to commencing the imaging process. As stated above, this feature of the invention will be discussed later. Moreover, if desired, all PFC liquids can be removed before imaging is begun.

Even if there is no PFC liquid present at the imaging site, the advantages of this invention can still be appreciated. For example, the degassed PFC liquid would have removed at least a part of a gas emboli which would
have distorted the image. Also, if the PFC liquid is removed, it will probably carry with it some loose particles from the site which would also have distorted the image.

While any suitable imaging devise can be used, there are some which benefit more form this invention. For example, ultrasonic imaging techniques work on the concept of reflected sound waves. Since the presence of gas emboli affects the way in which sound waves are reflected, the features of this invention are greatly appreciated by those who implement this imaging process.

On the other hand, as the name suggests, MRI imaging techniques work on the concept of magnetic resonance. Gas emboli effect sound waves more than they effect magnetic fields. Therefore, while it is still advantageous to employ the process of this invention when implementing an MRI imaging technique, sound wave-based imaging techniques benefit more from its use.

If the PFC liquid is retained at the imaging site during the imaging process, after the process is completed, it is removed from the patient's body cava. As stated above, the PFC liquid can be removed by any suitable means (e.g., physically, naturally, etc.).

As can be seen from the above, by practicing this embodiment of the invention, medical practitioners can now use diagnostic tools which were heretofore ineffective on patients plagued by the presence of gas emboli in and/or around the imaging site (e.g., ultrasonic techniques). Moreover, for those imaging techniques which are not as adversely effected by the presence of gas emboli (e.g., MRI techniques), practicing this embodiment of the invention can improve their clarity and/or effectiveness.

Yet another problem solved by this invention pertains to those instances where it is desirable to deliver biological agents to parts of a patient’s body cava which contain and/or are at least partially surrounded by gas emboli. For example, in many instances it is desirable to topically apply biological agents to certain parts of a patient’s body cava. Under conventional practices,
the presence of gas emboli may create a barrier prohibiting this type of treatment and/or may produce undesired complications.

In this embodiment of the invention, a mixture of a biological agent and a degassed PFC liquid is delivered to the site where the biological agent is to have its desired effect and which contains and/or is at least partially surrounded by gas emboli. As stated earlier, any suitable means can be used for degassing the PFC liquid and for delivering the liquid to its desired site.

When practicing this embodiment of the invention, the biological agent can be mixed with the PFC liquid either before, during or after the degassing procedure. For obvious reasons, if the biological agent is normally in a gaseous phase, it is preferred to mix this agent with the PFC liquid after the degassing process is completed.

On the other hand, if the agent is normally in a solid or liquid phase, in most instances it can be mixed with the PFC liquid at any time prior to introducing the mixture into the patient. However, in order not to create any complications during the degassing process, it is generally preferred to also mix these types of biological agents with the PFC liquid after it has been degassed.

Any suitable means can be used for introducing the biological agent into the PFC liquid. For example, the agent can be introduced in a time released manner or in a bulk form. The preferred method of introduction will depend, in part, upon the specific agent being introduced, upon the desired effect of the specific agent, and/or upon the patient's specific physiological conditions.

As used herein, the term "biological agent" refers to any agent which can be carried by and/or dissolved into the PFC liquid. Examples of suitable types of biological agents include, without limitation, medicaments, muscle relaxing agents, muscle contraction agents and image enhancing agents.

As before, once the agent-containing degassed PFC liquid comes into contact with the gas emboli, the absorption process will begin. The PFC liquid is permitted to remain at this site until at least a portion of the emboli
is absorbed thereby. Preferably, it is permitted to remain at this site until the emboli is completely absorbed or until equilibrium conditions are reached.

Prior to removing the PFC liquid from the patient's body cava, at least some of the biological agent is permitted to be released therefrom to the surrounding area. Therefore, in this embodiment, the PFC liquid is preferably removed from the patient's body cava only after it has (a) absorbed the desired amount of the gas emboli therein, and (b) released the desired amount of the biological agent therefrom. After the above has been completed, the PFC liquid can be removed from the patient's body cava by any suitable means.

Each of the embodiments of this invention can be practiced independently from, or in combination with, one another. For example, by practicing this invention, a medical professional can now (a) remove gas emboli from a patient's body cava, (b) image a site within a patient's body cava which contains or is surrounded by gas emboli, (c) deliver biological agents to a site within a patient's body cava which contains or is surrounded by gas emboli, and/or (d) deliver biological agents to a site within a patient's body cava which not only contains or is surrounded by gas emboli; but also, is to be imaged. One of the novel features of this invention is that all of the above can now be performed by a single process.

This invention can also be employed as a means for controlling, treating and/or diagnosing physiological conditions within a patient which is not troubled by the presence of gas emboli. Specifically, a further embodiment of this invention pertains to a novel means for imaging regions within a patient's body cava.

In this embodiment, a degassed PFC liquid is delivered to or around the site which is to be imaged. Then, prior to the degassed PFC liquid reaching atmospheric equilibrium through the absorption of miscellaneous body gases, the region to which the degassed PFC liquid was delivered is imaged. Thereafter, the degassed PFC liquid is removed from the patient's body.
In even a further embodiment of this invention, a degassed PFC liquid is mixed with a biological agent. Thereafter, the mixture is delivered to a region within the patient’s body cava which is to be treated and/or affected by the biological agent and which is to be imaged. While the agent-containing liquid is at the appropriate site, and before the agent-containing liquid has reached atmospheric equilibrium, that region of the patient’s body cava can be imaged. After the imaging process is completed and after the biological agent has had its desired effect, the PFC liquid is removed from the patient’s body cava.

It is also within the purview of this invention to use the degassed PFC liquid as a means for heating and/or cooling specific body cavities. Specifically, prior to introducing the degassed PFC liquid into the patient, the liquid’s temperature is adjusted accordingly. Therefore, in addition to the aforementioned features of this invention, it can also be designed to hypo- or hyper-thermically treat the patient.

The following examples are presented for illustrative purposes only. They are not to be construed as limiting the invention to the specific conditions involved therein.

**EXAMPLE 1**

The following data demonstrates the functional changes in bowel motility by practicing an embodiment of the present invention. This data was obtained in a male neonatal lamb. The subject was 5 days postnatal age and weighed approximately 4.8 kilograms.

Prior to performing any surgical procedure on the subject, it was anesthetized with pentobarbital sodium. This was accomplished by an intraperitoneal bolus of 25 mg/kg followed by maintenance intravenous administration of 3 mg/kg/hr.

The anesthetized subject was then gas ventilated and managed according to standard protocols to maintain physiologic gas exchange and acid-base conditions.
Thereafter, the animal was instrumented as follows to assess functional changes in bowel motility. First, under local anesthesia, a small incision was made in the subject's abdominal wall. The duodenum-pylorus junction was palpated and the duodenum was incised 2 cm below this junction.

A gas-filled balloon tipped catheter was then inserted. Its tip was positioned 10 cm caudal to the incision. Thereafter, a saline-filled catheter was inserted through the same incision. Its tip was positioned 20 cm caudal to the incision. Once both catheters were secured by purse string sutures, the subject's abdominal wall was clipped and closed.

The gas-filled balloon tipped catheter was connected to a Statham P23BC pressure transducer to measure pressure changes in response to agents which were manually infused through the saline-filled catheter. Pressure changes were used as an index of alterations in bowel motility pattern, following the infusion of: (a) a 5 ml bolus of neat PFC; (b) a 5 ml bolus of combined PFC and acetone (ACh:1.0 mg/kg); and (c) a 5 ml bolus of combined PFC and epinephrine (EPI:0.50 mg/kg).

Following the infusion of a 5 ml bolus of neat PFC liquid through the saline-filled catheter, there was a small but unsustained increase in motility. The monitored results from the pressure transducer are reproduced in Figure 1. Such a finding is common to any volume of fluid ostensibly associated with the stimulation of mechanoreceptors and myogenic responses.

Following the infusion of a 5 ml bolus of a PFC/epinephrine mixture (EPI: 0.5 mg/kg) through a saline-filled catheter, the change in the motility pattern was relatively small. The monitored results from the pressure transducer are reproduced in Figure 2. Such a response is generally associated with sympathomimetic relaxation of smooth muscle in the intestine.

Following the infusion of a 5 ml bolus of a PFC/acetone mixture (ACh:1.0 mg/kg) through the saline-filled catheter, the bowel motility and tone was increased. The monitored results from the pressure transducer are reproduced in Figure 3. This generally increases smooth muscle contraction in the bowel.
Although not preferred, the bowel could have been continuously imaged to synchronize functional pressure activity with dimensional alterations throughout the three conditions. If performed, functional changes could have been assessed relative to the mode of administering the agent (i.e., bolus vs. infusion of equivalent doses of the agent).

**EXAMPLE II**

In this example, *in vitro* and *in vivo* testing of saturated and unsaturated PFC liquids was performed.

Regarding *in vitro* testing, studies were performed on the acoustic characteristics of PFC liquids. These studies demonstrated that the presence of cavitation (i.e., the creation of gas bubbles freed from solution) is related to the amount of gas dissolved in the PFC liquid. The results of these studies are reproduced in the graphs illustrated in Figures 4 and 5.

As seen in Figure 4, at 25 °C and at an electrical intensity of about 3 W/cm², cavitation was detected in the gassed PFC liquid. However, at the same temperature and electrical intensity, cavitation was not detected in the degassed PFC liquid. The cavitation in the gassed PFC liquid resulted in a marked dissipation of power.

The data plotted in Figure 5 demonstrates that the threshold for cavitation is dependent upon gas saturation and temperature. Specifically, Figure 5 demonstrates that cavitation occurred more readily at higher percentages of gas saturation and temperature.

*In vivo* tests were performed on an anesthetized adult sheep which was intubated with a bifurcated bronchial catheter. There, a degassed PFC liquid was used to fill the cervical segment of the sheep's right apical lobe. Ultrasonic images were observed as the degassed PFC liquid filled the sheep's lung. While the lung was being filled, the sheep's lung region went from completely black to brightly lit.
Moreover, an image of a bag of a degassed PFC liquid suspended in an air-equilibrated water environment revealed a dark region while an image of the water environment revealed a white cloud. The cloudy image was associated to sound reflections from the air bubbles in the water. When the PFC liquid was not degassed, ultrasound imaging of the lung was unsuccessful.

It is evident from the foregoing that various modifications can be made to the embodiments of this invention without departing from the spirit and/or scope thereof which will be apparent to those skilled in the art. Having thus described the invention, it is claimed as follows.
THAT WHICH IS CLAIMED IS:

1. A process for at least the partial removal of gas emboli from a patient's body cava, said process comprising the steps of:
   (a) degassing a perfluorocarbon liquid,
   (b) delivering the degassed perfluorocarbon liquid to a region within the patient's body cava which contains a gas emboli,
   (c) permitting the degassed perfluorocarbon liquid to absorb at least a portion of the gas emboli to form an emboli-containing perfluorocarbon liquid, and
   (d) removing from the patient's body cava the emboli-containing perfluorocarbon liquid.

2. A process as recited in claim 1 wherein a biological agent is mixed with the perfluorocarbon liquid prior to step (b) and wherein at least some of the biological agent is permitted to be released from the perfluorocarbon liquid after step (b) but prior to step (d).

3. A process as recited in claim 2 wherein a biological agent is mixed with the perfluorocarbon liquid during step (a) and wherein at least some of the biological agent is permitted to be released from the perfluorocarbon liquid after step (b) but prior to step (d).

4. A process as recited in claim 2 wherein a biological agent is mixed with the perfluorocarbon liquid prior to step (a) and wherein at least some of the biological agent is permitted to be released from the perfluorocarbon liquid after step (b) but prior to step (d).

5. A process as recited in claim 1 wherein, prior to step (b), the perfluorocarbon liquid is heated to a temperature designed to hypothermically treat the patient.

6. A process as recited in claim 5 wherein a biological agent is mixed with the perfluorocarbon liquid prior to step (b) and wherein at least some of the biological agent is permitted to be released from the perfluorocarbon liquid after step (b) but prior to step (d).
7. A process as recited in claim 5 wherein a biological agent is mixed with the perfluorocarbon liquid during step (a) and wherein at least some of the biological agent is permitted to be released from the perfluorocarbon liquid after step (b) but prior to step (d).

8. A process as recited in claim 5 wherein a biological agent is mixed with the perfluorocarbon liquid prior to step (a) and wherein at least some of the biological agent is permitted to be released from the perfluorocarbon liquid after step (b) but prior to step (d).

9. A process as recited in claim 1 wherein, prior to step (b), the perfluorocarbon liquid is heated to a temperature designed to hyperthermally treat the patient.

10. A process as recited in claim 9 wherein a biological agent is mixed with the perfluorocarbon liquid prior to step (b) and wherein at least some of the biological agent is permitted to be released from the perfluorocarbon liquid after step (b) but prior to step (d).

11. A process as recited in claim 9 wherein a biological agent is mixed with the perfluorocarbon liquid during step (a) and wherein at least some of the biological agent is permitted to be released from the perfluorocarbon liquid after step (b) but prior to step (d).

12. A process as recited in claim 9 wherein a biological agent is mixed with the perfluorocarbon liquid prior to step (a) and wherein at least some of the biological agent is permitted to be released from the perfluorocarbon liquid after step (b) but prior to step (d).
FIG. IB
FIG. 2

INJECTION

1 MIN.

---
FIG. 3A

INJECTION

1 MIN.

[Diagram showing a graph with labeled injection point and time.]
FIG. 4

- **ACOUSTIC INTENSITY** [W/cm²]
- **ELECTRICAL "INTENSITY"** [W/cm²]

- **DEGASSED**, T = 25°C
- **SATURATED**, T = 25°C
- **DEGASSED**, T = 45°C
- **SATURATED**, T = 45°C

**LIQUID**: FC - 75
**FREQ.**: 1.0 MHz

**DETECTABLE CAVITATION**

FIG. 5

- **CAVITATION THRESHOLD** [W/cm²]
- **TEMPERATURE** [°C]

- **LIQUID**: FC - 43
- **FREQ.**: 900 KHz
- **SAT. GAS**: VENOUS B.G.
- **7% O₂, 7% CO₂, N₂ BAL.**

**95.8% SAT.**
**MAX POWER USED**
**98.3% SAT.**
**100% SAT.**
### A. CLASSIFICATION OF SUBJECT MATTER

<table>
<thead>
<tr>
<th>IPC(5)</th>
<th>A61M 31/00</th>
</tr>
</thead>
<tbody>
<tr>
<td>US CL</td>
<td>604/51</td>
</tr>
</tbody>
</table>

According to International Patent Classification (IPC) or to both national classification and IPC

### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)


Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

- APS, Lit, Search
- Degassed Perfluorocarbon liquid gas emboli

### C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category*</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>US, A 4,568,327 (SEUFERT), 04 FEBRUARY 1986, SEE COL. 4, LINES 65-69</td>
<td>1-12</td>
</tr>
</tbody>
</table>

- Further documents are listed in the continuation of Box C.
- See patent family annex.

### Date of the actual completion of the international search

12 AUGUST 1993

### Date of mailing of the international search report

01 NOV 1993

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks

Box PCT

Washington, D.C. 20231

Facsimile No. NOT APPLICABLE

Authorized official

MARK O. POLUTTA

Authorized office

(703) 305-0058

Form PCT/ISA/210 (second sheet) (July 1992)